Unidade Local De Saude Do Alto Ave E.P.E.
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Heart Failure Research at Unidade Local De Saude Do Alto Ave E.P.E.
This site in Guimaraes, Portugal is active in cardiology studies focused on cardiovascular diseases, including acute coronary syndrome, hypertension, atherosclerotic cardiovascular disease, heart failure, and transthyretin amyloid cardiomyopathy. The trials are designed to test new treatments, reduce major cardiac events, and improve long-term disease control.
- Preventing heart attacks, stroke, and other major cardiovascular events
- Evaluating therapies for heart failure and cardiomyopathy
- Studying lipid-lowering and risk-reduction strategies in high-risk patients
Research here also includes imaging-based assessment of treatment response and studies aimed at better understanding cardiac function and disease progression.
Oncology and Precision Cancer Treatment
A major share of the research landscape covers neoplasms, especially breast cancer, gastric and gastroesophageal junction cancer, non-small cell lung cancer, small cell lung cancer, metastatic colorectal cancer, and urothelial carcinoma. These trials are centered on evaluating new targeted therapies and combinations intended to improve survival and disease control.
- Testing targeted approaches in HER2-positive and hormone receptor-positive breast cancer
- Assessing new treatment options for advanced gastric cancer and GEJ adenocarcinoma
- Studying novel strategies for advanced lung cancer and metastatic solid tumors
The site’s oncology portfolio reflects a strong interest in personalized medicine, with studies aimed at improving treatment effectiveness and delaying cancer recurrence.
Digestive System Diseases, Liver Disorders, and Inflammatory Bowel Disease
Clinical trials in digestive system diseases include Crohn’s disease, ulcerative colitis, non-alcoholic steatohepatitis, primary sclerosing cholangitis, and primary biliary cholangitis. The research is focused on improving symptom control, reducing inflammation, and testing treatments that may slow disease progression or improve liver health.
- Evaluating therapies for inflammatory bowel disease
- Studying treatment options for NASH and other chronic liver conditions
- Assessing long-term safety and effectiveness of emerging digestive disease therapies
This area includes work on both gastrointestinal inflammation and metabolic liver disease, showing broad interest in chronic digestive and hepatology research.
Respiratory Diseases, Allergy, and Airway Inflammation
The site also supports trials in respiratory tract diseases, including chronic obstructive pulmonary disease, severe asthma, bronchiectasis, pneumonia, and chronic rhinosinusitis. These studies aim to improve breathing symptoms, lower exacerbation rates, and assess new anti-inflammatory or supportive therapies.
- Testing treatments for COPD and asthma control
- Evaluating therapies to reduce flare-ups and improve lung function
- Studying approaches for sinus and airway inflammation
Research in this field spans chronic lung disease and upper-airway disorders, with a focus on better day-to-day symptom management.
Metabolic and Endocrine Research
Trials in nutritional and metabolic diseases include obesity, type 2 diabetes, familial chylomicronemia syndrome, and dyslipidemia. These studies are designed to evaluate therapies that may improve metabolic health, reduce cardiovascular risk, and protect against complications such as diabetic eye disease.
- Exploring treatments for obesity and metabolic risk
- Assessing therapies for type 2 diabetes and related complications
- Studying lipid and triglyceride lowering strategies
The metabolic portfolio connects closely with cardiovascular research, reflecting the overlap between blood sugar control, weight management, and heart health.
Nervous System and Mental Health Studies
Research in nervous system diseases and mental disorders includes Alzheimer’s disease, Parkinson’s disease, migraine, multiple sclerosis, and psychosis related to dementia. These trials are aimed at improving symptoms, preserving function, and evaluating new options for cognitive and behavioral conditions.
- Studying treatments for Alzheimer’s-related cognitive and behavioral symptoms
- Evaluating options for Parkinson’s disease and migraine
- Assessing therapies for neurologic recovery after stroke or brain injury
This area includes both neurodegenerative disease and symptom-focused care, with an emphasis on quality of life and long-term management.
Immune-Mediated, Rheumatologic, and Skin Disease Research
The site conducts studies in immune system diseases, musculoskeletal diseases, and skin and connective tissue diseases, including rheumatoid arthritis, systemic lupus erythematosus, hidradenitis suppurativa, psoriasis, and ulcerative colitis. These trials generally aim to reduce inflammation, relieve symptoms, and improve long-term disease control.
- Testing new therapies for chronic autoimmune inflammation
- Evaluating treatments for rheumatoid arthritis and lupus
- Studying options for psoriasis and other inflammatory skin conditions
The research portfolio highlights a broad interest in immune-driven diseases that affect the joints, skin, and internal organs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 190 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 171 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG8trials
lock +22 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Unidade Local De Saude Do Alto Ave E.P.E.
lock Showing 1 of 115 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 190 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 6 | Unknown | 2018-09-21 | 2025-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
